Isolated REM sleep behavior disorder is a known prodrome of Parkinson's disease — patients who act out their dreams have a high probability of developing clinical neurodegeneration within a decade. The question is what connects sleep disruption to dopamine loss.
Ambulatory circadian monitoring of 42 iRBD patients reveals a coupling that standard clinical assessments miss. The activity-to-totality index — a measure of circadian rhythm amplitude — correlates simultaneously with the DTI-ALPS glymphatic clearance proxy and with putaminal dopaminergic uptake measured by DaT-SPECT imaging.
Three systems. One correlation. The circadian clock, the brain's waste-clearance plumbing, and the dopamine system are not three separate pathologies converging in Parkinson's. They are one coupled system failing together, years before clinical symptoms appear.
The glymphatic system — the brain's drainage network that clears metabolic waste during sleep — depends on sleep architecture for its function. Circadian disruption degrades sleep architecture. Degraded sleep architecture reduces glymphatic clearance. Reduced clearance allows toxic protein accumulation. The accumulation damages dopaminergic neurons. The damaged neurons further disrupt sleep. The loop closes.
The clinical implication: circadian rhythm monitoring with a wrist accelerometer — a $30 device worn for seven days — may detect prodromal neurodegeneration that currently requires a $3,000 DaT-SPECT scan. The rhythm is not a symptom of the disease. It's a window into the maintenance schedule that, when disrupted, permits the disease.
The through-claim: when three systems correlate in their decline, the temptation is to find a common upstream cause. But in coupled systems, there may be no upstream — only a loop where each component's degradation accelerates the others. The rhythm isn't causing the damage. The rhythm is the damage, measured at a different scale.